Tumor-Evoked Regulatory B Cells Promote Breast Cancer Metastasis by Converting Resting CD4+ T Cells to T-Regulatory Cells

Purevdorj B. Olkhanud1, Bazarragchaa Damdinsuren2, Monica Bodogai1, Ronald E. Gress4, Ranjan Sen6, Katarzyna Wejksza1, Enkhzol Malchinkhuu1, Robert P. Wersto3, and Arya Biragyn1

Abstract

Pulmonary metastasis of breast cancer requires recruitment and expansion of T-regulatory cells (Treg) that promote escape from host protective immune cells. However, it remains unclear precisely how tumors recruit Tregs to support metastatic growth. Here we report the mechanistic involvement of a unique and previously undescribed subset of regulatory B cells. These cells, designated tumor-evoked Bregs (tBreg), phenotypically resemble activated but poorly proliferative mature B2 cells (CD19+ CD25high CD69high CD62Llow CD1dhigh CD5low CD11blow IgMhigh) that express constitutively active Stat3 and B7-H1high CD81high CD86high CD62Llow IgMint. Our studies with the mouse 4T1 model of breast cancer indicate that the primary role of tBregs in lung metastases is to induce TGF-β-dependent conversion of FoxP3+ Tregs from resting CD4+ T cells. In the absence of tBregs, 4T1 tumors cannot metastasize into the lungs efficiently due to poor Treg conversion. Our findings have important clinical implications, as they suggest that tBregs must be controlled to interrupt the initiation of a key cancer-induced immunosuppressive event that is critical to support cancer metastasis. Cancer Res; 71(10); 3505–15. ©2011 AACR.

Introduction

Cancer escape is an active process that regulates immune responses by employing at least 2 types of suppressive cells, myeloid suppressive cells (MSC) and T-regulatory cells (Treg; ref. 1–3). For example, in the mouse mammary adenocarcinoma 4T1 cancer model, which represents a highly aggressive model of human breast carcinoma (4), cancer-produced granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin-1β (IL-1β), and TGF-β promote the generation of MSCs to impair antitumor immune responses and promote metastases either through direct action or indirectly by activating Tregs (5). Tregs are key subsets of CD4+ T cells that control peripheral tolerance to self- and alloantigens (6), and the majority of them phenotypically can be identified by the expression of CD25 (IL-2Rα) and a fork-head box P3 (FoxP3) gene product (7). They suppress T-cell responses by acting directly or through the inhibition of antigen-presenting cells (APC; ref. 7–9) involving cell contact, FasL/Fas-, and PD1/B7-H1–dependent processes (10–13), or secreted factors such as IL-10, TGF-β, IL-27, and IL-35 (14–17). As a result, Tregs are considered to play a key role in the escape of cancer cells from antitumor effector T cells (20–23), although the role of other immune cells remains poorly understood. Although a handful of reports indicate that B cells can disable CD4+ T-cell help for CTL-mediated tumor immunity in mice (18), or promote epithelial carcinogenesis and castration-resistant prostate cancer (19, 20), the role or existence of cancer-associated regulatory B cells (Breg) remains unknown. However, suppressive B cells and Bregs were shown to exist and participate in the protective immune responses against autoimmune diseases (21–24). For example, T cell–dependent autoimmunity in mice is associated with the lack of a small subset (1%–2% of B220+ cells) of IL-10–producing CD1dhigh CD5+ B cells (so-called B10 cells; ref. 25). In addition, B1b (CD5+ CD1dhigh B220low CD11b+ IgM+) suppressive cells in mice and CD19+ CD24high CD38high B cells in humans are linked with protection from murine chronic colitis (26, 27) and systemic lupus erythematosus, respectively (28). Interestingly, although the suppressive activity of B cells can be IL-10 independent, for example, in protection from experimental autoimmune encephalitis (29), the majority of them appear to utilize IL-10 (23–25, 28). In fact, lipopolysaccharide (LPS) activation of naïve B cells alone can induce IL-10 production and suppress T-cell responses inducing H-Y antigen tolerance (30).

Recently, we have reported that lung metastasis of mammary adenocarcinoma 4T1 implanted in the mammary gland of immune competent BALB/c mice requires an active participation of Tregs to inactivate antitumor defenses of natural killer (NK) cells (4). The process was also associated with the expansion of Tregs that appeared to be induced without...
involvement of MSCs (4). Here, we show that FoxP3+ Treg conversion from nonregulatory CD4+ T cells (non-Tregs) is mediated by a unique subset of regulatory B cells, designated tumor-evoked Bregs (tBregs), utilizing TGF-β, a pathway commonly used for the generation of Tregs (31). To our knowledge, this is the first report on the existence and function of Bregs in cancers. Our data suggest that as long as cancer persists, it will generate tBregs to thereby convert Tregs to initiate a chain of suppressive events leading to successful lung metastasis.

Materials and Methods

Reagents, cells, and mice

The majority of reagents were described in our recent report (3). In brief, female BALB/c, C57Bl/6, nonobese diabetic severe combined immunodeficient [NOD/SCID (NOD.CB17-Prkdcscid/J; H-2d)] mice and mice with mature B-cell deficiency (B6.129P2-Igh-fmwtjg/j) were from the Jackson Laboratory. 4T1 cells, B16F10 melanoma, MCF-7 and MDA-MB-231, OVCAR3, B-2008, BG-1 UC101, and SW480 cells were purchased from American Type Culture Collection. 4T1.2 cells, a subset of 4T1 cells, were a gift from Dr. Robin L. Anderson (Peter McCallum Cancer Centre, East Melbourne Victoria, Australia). 4T1-PE cells were generated from 4T1 by using TARC-PE38 chemotoxin (3). Splenocytes from FoxP3-GFP mice were a gift from Dr. Rachel Caspi (NEI/NIH) and Dr. Vijay Kochroo (Harvard Medical School). Primary untransformed murine embryonic fibroblasts CD1 and DR4 were used at passages 3 to 6 and were the gift of Dr. Lioudmila Sharova (NIA/NIH).

In vitro tBreg and Treg generation and T-cell suppression assay

Murine splenic B cells were isolated by negative selection using the RoboSep magnetic purification system (StemCell Technologies). For tBreg generation, B cells were incubated with 50% cancer conditioned media (CM) for 2 days in complete RPMI (cRPMI). Control B cells were treated with PBS, or 100 ng/mL B-cell activating factor belonging to the TNF family (BAFF), or 500 ng/mL B-cell activating factor (BAFF). Cancer CM was collected from con

To generate Tregs, tBregs were incubated with non-Treg cells (CD25+CD4+ from BALB/c mice or GFP+CD4+ cells from FoxP3-GFP mice, purity >99.5%) at a 1:1 ratio and cultured for 5 days in the presence of bead-conjugated anti-CD3/CD28 Abs and 500 U/mL IL-2 in the absence or presence of DMSO or SB439542 (Tocris Bioscience). To test their activity, Tregs were reisolated by 2 rounds of B-cell depletion with fluorescent isothiocyanate conjugated FITC)CD19 and PE-B220 Abs (BD Pharmingen) and anti-FITC and anti-PE beads (Miltenyi Biotec) and mixed with naïve CFSE-labeled CD8+ T cells in the presence of bead-conjugated anti-CD3/CD28 Abs and 500 U/mL IL-2 for 5 days. TGF-β1 secretion was quantified by ELISA following manufacturer’s protocol (R&D systems, Inc.).

In vivo manipulations

Animal care was provided in accordance with the procedures outlined in the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 86-23, 1985). The experiments were carried out using 4- to 8-week-old female mice in a pathogen-free environment at the National Institute on Aging Animal Facility (Baltimore, MD). To deplete Tregs and tBregs, mice were intraperitoneally (i.p.) injected with Abs to mouse CD25 (500 μg; PC-61, BioXcell) and B220 (400 μg; RA3.3A1, BioXcell) or control IgG at days 3, 10, and 18 posttumor challenge. To restore metastasis, NOD/SCID mice were i.v. injected with 1 × 10^5 tBregs, generated from naïve BALB/c B cells treated for 2 days with CM-4T1PE, together with equal amounts of BALB/c non-Tregs at days −1, 3, and 7 after tumor challenge. Control NOD/SCID mice were injected with 1 × 10^7 BALB/c non-Tregs. Congenic mice were challenged with s.c. 4T1.2 tumor cells (in fourth mammary gland with 1 × 10^3 cells) or 1 × 10^3 B16 melanoma F10 cells; tumor growth was measured every other day. Mice were culled after 28 days of tumor challenge and lungs were analyzed for metastasis as previously described (3). Tumor burden in the lungs was quantified by counting nodules.

Results

Lung metastases require the participation of a unique subset of B cells

We recently reported that murine 4T1 breast cancer promotes expansion of Tregs to utilize them in lung metastases (3). Interestingly, although this expansion can be induced by MSCs, which are also expanded in tumor-bearing mice, MSCs appear not to be involved in the de novo conversion of Tregs (3). The search for other Treg-converting APCs led us to find an enhanced population of CD25-expressing B220+CD19+ B cells in the peripheral blood and secondary lymphoid organs of tumor-bearing mice (Fig. 1A). Similar cells were also readily generated in naïve mice s.c. injected with CM of 4T1 cells (CM-4T1, and specifically, by their nonmetastatic 4T1 cells. CM-4T1PE (Fig. 1B) and CM-4T1B4 (Supplementary Fig. S1)) or in vitro from purified naïve mouse B cells treated with cancer CM (Fig. 1C). CD25 expression can also be induced in B cells treated with mitogens like LPS (Fig. 1C). However, unlike LPS, tumor CM–treated B cells only upregulated CD25 without...
proliferation (Fig. 1C). It appears that this was the 4T1 cancer CM-associated process, as CM from untransformed murine fibroblasts or murine A20 B-cell lymphoma did not activate B cells either in vitro or in vivo (data not shown; also see Supplementary Fig. S2). To test whether tumor-induced CD25^+ B220^+ B cells are involved in lung metastases, 4T1

Figure 1. A, 4T1 cancer-bearing mice (black bars) have a higher proportion of CD25^+ B220^+ cells (% ± SEM of 3 mice per group) in peripheral blood and secondary lymphoid organs (Ax, axillary; In, inguinal; and Mes, mesenteric) compared with naïve BALB/c mice (gray bars). B, CM from nonmetastatic 4T1-PE cells (CM-4T1PE) had a greater ability to generate CD25^+ CD19^+ B220^+ cells in vivo, than CM from metastatic 4T1 cells (CM-4T1). Shown is proportion of cells within CD19^+ cells. Naïve BALB/c mice were i.p. injected with 0.5 mL CMs or control medium (Mock) once a day 4 times and splenocytes were stained for CD25 and B220 cells 5 days after last treatment. C, poorly proliferative CD25^+ B220^+ B cells were generated in vitro from naïve mouse B cells after treatment with CM-4T1PE for 2 days. Control B cells were treated with LPS (B-LPS), or PBS (B-PBS). Histograms show percentage of proliferated (CFSE diluted) B cells. Numbers are for percentage of cells in corresponding quadrants. The results in (A–C) were repeated at least 3 times. D and E, B220^+ CD25^+ tbregs are required for lung metastasis. D, mean lung metastatic foci ± SEM of 4 mice per group; experiments reproduced 3 times. 4T1.2 tumor-bearing BALB/c mice were depleted of B220^+ and CD25^+ cells by i.p. injecting anti-B220 and anti-CD25Abs alone or together (aCD25 + aB220), respectively. Control mice were treated with isotype-matched antibody (IgG). E, y-axis shows % ± SEM of CD25^+ B220^+ cells (within CD19^+ cells) in spleens of 4 tumor-bearing and naïve mice per group treated with anti-B220 Ab or IgG. From here on, *, P < 0.05; **, P < 0.01; ***, P < 0.001.
tumor-bearing mice were treated with Ab targeting B220 alone (to deplete B cells) or in combination with CD25 (PC61 Ab, routinely used for Treg depletion). Although control Ab-treated mice succumbed to massive lung metastases, both anti-B220 and anti-CD25 Abs, which depleted splenic B220⁺ and CD25⁺ cells (Supplementary Fig. S3a), almost completely abrogated lung metastases (Fig. 1D). Importantly, treatment with anti-B220 Ab also reversed the enhanced proportion of CD25-expressing B220⁺CD19⁺ cells in tumor-bearing mice to the levels of naïve mice (Fig. 1E and Supplementary Fig. S3b), further indicating the importance of CD25⁺ B cells in lung metastases.

Cancer induces the generation of regulatory B cells

Next, to explain the metastasis-promoting role of B cells, we hypothesized that CD25⁺ B cells could have regulatory activity. To test this idea, 3 types of B cells were generated in vitro by treating purified naïve B cells with control CM, LPS, or cancer cell–derived CM [from here on, only the data from the use of CM-4T1PE will be shown, as it consistently activated B cells more strongly (Fig. 1B and C)]. The cells were then washed and mixed with CFSE-labeled CD3⁺ T cells in the presence of anti-CD3/CD28 Ab to activate TCR-mediated proliferation. Unlike B cells treated with control CM (B-PBS) or LPS (B-LPS, Fig. 2A), the cancer CM–treated B cells almost completely prevented T-cell proliferation (B-4T1PE, Fig. 2A) in both CD4⁺ and CD8⁺ cells (Supplementary Fig. S4 and data not shown). The inhibitory activity was only retained in the CD25⁺, but not CD25⁻, subset of cancer CM-treated B cells (Fig. 2B). In contrast, control B cells that were treated with CM from untransformed fibroblasts (Supplementary Fig. S2) or LPS (Fig. 2B) did not inhibit T-cell proliferation regardless of CD25 expression. Moreover, confirming a positive association between CD25⁺CD19⁺ B220⁺ B cells and lung metastases (Fig. 1A, D, and E), CD19⁺ B cells isolated from 4T1 tumor-bearing mice (Fig. 2C) or cancer CM–injected mice (CM-4T1PE, Fig. 2D) efficiently inhibited T-cell proliferation ex vivo. Control B cells from naïve or control CM–treated mice failed to affect T-cell activity (Fig. 2C and D). Importantly, the inhibition was completely prevented if B220⁺ B cells were removed from the suppression assay (anti-B220, CM-4T1PE, Fig. 2D). Taken together, 4T1 cancer

Figure 2. A, CM-4T1PE, but not mock (B-PBS) or LPS (B-LPS), treated B cells (B-4T1PE) inhibit proliferation of T cells stimulated with anti-CD3/CD28 Abs. B cells and CFSE-labeled T cells (responder) were cultured at a 1:1 ratio for 4 days in the presence of 50 U/mL IL-2. B, the suppressive activity of B-4T1PE is retained in CD25⁺ subset. CD25⁺ and CD25⁻ subsets of B-LPS and B-4T1PE cells were purified using anti-CD25 Ab and tested as in (A). C, B cells isolated from 4T1 tumor-bearing mice also suppress T-cell activity. Splenic CD19⁺ were isolated from 4T1 tumor-bearing mice and tested as in (A) after mixing with CFSE-labeled T cells in 1:1 and 1:5 B- and T-cell ratio, whereas control naïve mouse B cells were used at 1:1 ratio. D, splenic CD19⁺ B cells were isolated from naïve BALB/c mice i.p. injected with control CM or cancer CM (CM-4T1PE, see Fig. 1B) and tested in vitro for the ability to inhibit T-cell proliferation as in (A). Purified B cells from CM-4T1PE–treated mice were also depleted using anti-B220 Ab or control IgG prior to mixing with T cells. Controls were B cells in vitro cultured with BAFF (to maintain viability of control cells) or CM-4T1PE (B-BAFF and B-4T1PE, respectively). Shown is % ± SEM of proliferated T cells of triplicates repeated at least 3 times.
cells directly induce the generation of a unique and suppressive subset of CD25\(^+\)B220\(^-\)CD19\(^-\)B cells. These cells (from here on designated tBregs) inhibit proliferation of resting and preactivated T cells equally well in a mouse strain-independent way (Supplementary Fig. S4A–D) even when used at a 1:16 ratio of B cells to T cells (Supplementary Fig. S5). Unlike resting B cells, tBregs retained high viability (at least up to 96 hours; Supplementary Fig. S6) and expressed constitutively active Stat3 (Fig. 3A). Phenotypically the cells resembled activated mature B2 cells (IgD\(^{\text{High}}\) and CD21\(^{\text{Int/low}}\), CD23\(^{\text{Int/low}}\) CD43\(^-\) and IgM\(^{\text{Int}}\); Fig. 3B), as they reduced expression of CD62L and upregulated CD69, B7-H1, and CD81 (Fig. 3B).

This does not appear to be an isolated mouse phenomenon, as healthy donor peripheral blood CD19\(^+\) B cells treated with CM from a number of human cancer cells, including ovarian and colon, upregulated CD25 (Supplementary Fig. S7A) and suppressed proliferation of human CD3\(^+\)T cells stimulated with anti-CD3/CD28 Abs and IL-2 (Fig. 3C and D). As with mice, B cells treated with LPS did not suppress T-cell activity (Fig. 3C and D). Thus, human cancers also induce the generation of tBregs.
tBregs induce the generation of FoxP3⁺ Tregs

Next, to test the mechanism of Breg-mediated suppression, we separated tBregs from T cells by a porous membrane, and found that this disabled the suppressive activity of tBregs (Fig. 4A). Thus, the process required cell contact to exert T-cell suppression. However, all our attempts to link the suppression with known mechanisms failed. For example, tBregs did not affect viability of T cells and did not utilize common regulatory pathways, such as B7-H1 (Fig. 4B), and Fas (Supplementary Fig. S7B and C), or soluble cytokines IL-10, IL-27, and IL-35 (the factors abundantly expressed in tBregs; Supplementary Fig. S7D–F). Finally, the IL-2 competition theory can be also ruled out, as the suppression was not affected by the presence of high doses of IL-2 (Fig. 4B; Supplementary Fig. S7D).

On the other hand, tBregs expressed high levels of CD40, CD80, CD86, and MHC class I and II molecules (Fig. 3B) and high levels of TGF-β (Fig. 4C), suggesting that tBregs could be promoting Treg conversion. To test this idea, purified non-regulatory CD4⁺ T cells (CD25⁻/FoxP3⁻/CD4⁺, non-Tregs)
were stimulated with anti-CD3/CD28 Abs and high doses of IL-2 in the presence of tBregs or mock-treated B cells. Unlike T cells incubated with control B cells (B-PBS), a significant number of non-Tregs cocultured with tBregs expressed FoxP3 (tBregs; Fig. 4D), a key marker of Tregs (7). This is not a result of the expansion of contaminating preexisting Tregs, as their proportion in our non-Treg preparations was below 0.01% (see also Fig. 5A) and, compared with control B cells, tBregs did not enhance (if not reduced) proliferation of purified FoxP3⁺CD25⁻CD4⁺ cells stimulated with anti-CD3/CD28 Abs in the presence of high doses of IL-2 (Fig. 4E). Importantly, highly purified green fluorescent protein–negative (GFP⁻) CD4⁺ T cells from FoxP3-GFP mice (32) were also induced to express GFP/FoxP3 when only incubated with tBregs, but not control B cells (Fig. 5A). To confirm that these newly converted FoxP3⁺ T cells also acquired regulatory activity, the CD4⁺ T cells (non-Tregs cocultured with control B cells or tBregs) were reisolated by 2 rounds of B-cell depletion (using anti-CD19 and -B220 Abs which resulted in at least 98% pure T cells) and tested for their ability to inhibit proliferation of

---

**Figure 5.** A, purified GFP⁻/CD4⁺T cells from FoxP3-GFP were depleted of CD25⁺ cells (<0.01%, right dot blot, inset) and stimulated with anti-CD3/CD28 Abs and IL-2 (500 U/mL) in the presence of tBregs or control B cells. y-axis shows % ± SEM of GFP⁺ (FoxP3⁺) Tregs after 5 days of culture of a triplicate assay. Left dot blot (inset) shows proportion of GFP⁻/CD25⁺ of purified CD4⁺ cells before CD25 depletion. B, the converted FoxP3⁺ T cells (as in Fig. 4D) are Tregs, as they (after 2 rounds of depletion of B cells, >98% pure CD4⁺ cells) suppressed proliferation of CFSE-labeled CD8⁺ T cells of a triplicate experiment repeated twice. P values are for comparisons between tBreg- (black bars) and normal B cell–treated (gray bars) CD4⁺ T cells. tBreg-mediated Treg conversion from non-Tregs [% of GFP⁺ CD4⁺ T cells in (A) or FoxP3⁺ CD4⁺ cells in C, y-axis] requires TGF-β signaling, as it was blocked with 10 μM SB431542. D, unlike B-PBS, tBregs expand FoxP3⁺ CD4⁺ T cells in vivo. Three naïve BALB/c mice per group were i.p. injected with 10⁷ B cells and the proportion of FoxP3⁺ CD4⁺ T cells [% ± SEM, y-axis] was evaluated after 5 days in the blood and spleens by FACS. All data shown are representative of at least 3 experiments.

---

Cancer Res; 71(10) May 15, 2011 3511

www.aacrjournals.org

Published OnlineFirst March 28, 2011; DOI: 10.1158/0008-5472.CAN-10-4316
naïve CD8+ T cells. Indeed, the tBreg-generated FoxP3+ T cells, but not with T cells incubated with control B cells, inhibited proliferation of CD8+ T cells (Fig. 5B). The process required TGF-β, as the ability to convert Tregs was completely blocked in the presence of ALK5 inhibitor SB431542, a selective inhibitor of the TGF-β type I receptor activity (Fig. 5A and C). Moreover, the fact that naïve BALB/c mice transferred with tBregs, but not mock-treated B cells, had significantly enhanced numbers of FoxP3+ Tregs in peripheral blood (and at lesser degrees in spleens, although not statistically significant; Fig. 5D), suggest that tBregs also promote Treg conversion in vivo as in cancer-bearing mice.

**tBreg-induced Tregs promote lung metastasis**

Because lung metastasis of 4T1 cancer cells is a Treg-dependent process that is also associated with the expansion of Tregs (3), the role of tBregs in lung metastasis (see Fig. 1D and E) is to promote conversion of Tregs. To show this, we utilized T- and B-cell–deficient H-2d-matched NOD/SCID mice that do not support metastasis of 4T1 cancer cells unless adoptively transferred with Tregs (3). Although control mice transferred with either tBregs alone (data not shown) or non-Tregs were almost free of lung metastases (Fig. 6A), the mice that received ex vivo–generated Tregs together with non-Tregs from BALB/c mice succumbed to massive lung metastasis (Fig. 6A), suggesting that the process used tBreg-induced Tregs. Indeed, consistent with our report on the importance of Tregs in lung metastases (3), the transfer of newly in vitro converted Tregs (cultured with tBregs and then depleted of tBregs, >98%; Fig. 5B), but not normal B cell–treated T cells, also restored the ability of 4T1 cells to metastasize in NOD/SCID mice (Fig. 6B). Thus, taken together with the inability of 4T1 cancer cells to metastasize in immune competent BALB/c mice depleted of B220+ B cells (Fig. 1D), our data suggest that the role of tBregs in lung metastases is to induce Treg conversion. This is not a 4T1 cancer–associated phenomenon, as B16 melanoma could not efficiently progress in mice that did not have mature B cells (33), unless they were adoptively transferred with congenic tBregs generated by treating them with cancer CM (JHT KO + tBregs; Fig. 6C).

**Discussion**

We previously reported that murine breast cancer induces expansion of Tregs to utilize them in lung metastasis (3). The search for the cells responsible for this expansion has led us to find a new subset of regulatory B cells, tBregs, which are actively generated from normal B cells in response to the direct effects of cancer-produced factors. tBregs also play an essential role in lung metastases, as they at least induce conversion of metastasis-supporting FoxP3+ Tregs from non-Treg CD4+ T cells. Although tBregs did not affect expansion of preexisting (purified) Tregs in vitro, their role on Tregs in vivo cannot be ruled out. However, using highly purified CD4+ T cells (which contained less than 0.01% contaminating Tregs) from spleens of naïve BALB/c and FoxP3-GFP mice, we showed that tBregs mediate de novo Treg conversion utilizing TGF-β–dependent process, suggesting that they may repre-
Collectively, as summarized in Fig. 6D, our findings indicate that tumor-evoked regulatory B cells are crucial for lung metastasis, acting to convert resting T cells to regulatory T cells that promote immune escape in the target tissue. However, the tBregs by themselves are actively generated from normal B cells in response to cancer cell–produced factors utilizing yet unknown mechanisms, and this appears to be quite a widespread phenomenon, as a number of human cancer lines (breast, ovarian, and colon carcinomas) also induced the generation of tBregs. Thus, the clinical implication of our finding is that, as long as cancer persists, it will induce the generation of tBregs and thereby initiate the chain of suppressive events leading to metastasis. Hence, tBregs need to be controlled to efficiently combat cancers, as in the absence of tBregs, cancer...
cannot metastasize into the lungs due to a poor Treg conversion. For example, clinically available antibodies such as the pan B-cell antibody, anti-CD20 antibody (rituximab) or the anti-IL-2Rα antibody (daclizumab) could bypass the Treg-mediated blockade of the immune response to some cancers.

**Disclosure of Potential Conflicts of Interest**

The authors work for the U.S. government and declare no competing financial interests.

**Acknowledgments**

The author thank Drs. Edward Goetzl (UCSF), Dan Longo (NIA/NIH), and Ana Lustig (NIA/NIH) for helpful comments and suggestions; Drs. Ashani Weeraratna and Linoudmila Sharova (NIA/NIH) for the gift of melanoma cell lines and murine embryonic fibroblasts, respectively; Karen Madara (NIA/NIH) for providing human blood samples; Dr. Cornelia Bergmann (Lerner Research Institute) for the gift of B7-H1 KO splenocytes; and Drs. Rachel Caspi (NEI/NIH) and Vijay Kochroo (Harvard Medical School) for the gift of FoxP3-GFP splenocytes.

**Grant Support**

This research was supported by the Intramural Research Program of the National Institute on Aging, NIH.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 30, 2010; revised March 11, 2011; accepted March 17, 2011; published OnlineFirst March 28, 2011.

**References**


Tumor-Evoked Regulatory B Cells Promote Breast Cancer Metastasis by Converting Resting CD4+ T Cells to T-Regulatory Cells

Purevdorj B. Olkhanud, Bazarragchaa Damdinsuren, Monica Bodogai, et al.


Updated version
Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-10-4316

Supplementary Material
Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2011/03/28/0008-5472.CAN-10-4316.DC1

Cited articles
This article cites 36 articles, 15 of which you can access for free at: http://cancerres.aacrjournals.org/content/71/10/3505.full#ref-list-1

Citing articles
This article has been cited by 18 HighWire-hosted articles. Access the articles at: http://cancerres.aacrjournals.org/content/71/10/3505.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.